Earnings · US stocks

Xeris Biopharma Holdings, Inc. (XERS) earnings

Xeris Biopharma Holdings, Inc. published its quarterly report on 2026-11-05. The stock moved +51.63% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-05
Result
Great
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day+25.05%—
3 days+51.63%—
7 days+59.27%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 5 of them. The stock rose in the 3 trading days after 5 of 8 reports (average +13.75%).

PublishedEPSEPS surprise3 days after30 days after30d vs index
2026-11-050.06+124.97%+51.63%——
2026-05-070.01+1592.54%-3.61%+9.11%+7.35%
2026-03-020.06+33.33%-0.82%-2.45%-2.47%
2025-08-07-0.01+66.67%+31.15%+51.18%+46.53%
2025-05-08-0.06-50.00%+10.49%+0.67%-5.23%
2025-03-06-0.03-50.00%+21.75%+8.22%+18.07%
2024-11-08-0.06+21.05%-6.25%+3.87%+4.62%
2024-08-08-0.10-6.38%+5.63%+38.97%+28.88%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: XERS

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.